15 results
PrimaryThe primary objective is to compare both ixekizumab regimens (80 mg Q2W or 80 mg Q4W) versus placebo in patients with active rad-axSpA at Week 16.SecondaryThe major secondary objective is:To compare both ixekizumab regimens (80 mg Q2W or 80…
The primary objective is to compare both ixekizumab regimens (80 mg Q2W or 80 mg Q4W) versus placebo in patients with active nonrad-axSpA at Week 16The major secondary objectives is to compare both ixekizumab regimens (80 mg Q2W or 80 mg Q4W versus…
The primary objectives of this study are to assess whether 80 mg ixekizumab every 2 weeks (Q2W) is:• noninferior to ustekinumab at Week 12 in the treatment of patients with moderate-to-severe plaque psoriasis as measured by proportion of patients…
The primary objective of the study is to assess whether ixekizumab 80 mg every 2 weeks (Q2W) or80 mg every 4 weeks (Q4W) is superior to placebo in the treatment of biologic disease-modifying antirheumatic drug (bDMARD)-naive patients with active…
To Evaluate the differences between teh length of delirium in the anti-psychotics+ melatonin group and the anti-psychotics + placebo group.
The goals of the proposed study are: (1) to further elucidate the relations between impulse control, motivational strength of drug cues, and brain activation patterns (using fMRI); (2) to examine the relative strength by which these processes are…
PrimaryThe primary objective is to compare both ixekizumab regimens (80 mg every 2 weeks [Q2W] or 80 mg every 4 weeks [Q4W]) versus placebo in patients with active radiographic axial spondyloarthritis (rad-axSpA) at Week 16.SecondaryThe major…
To investigate the effect of modafinil (200 mg) and caffeine (300 mg) on vigilance in low, medium and high caffeine consumers during the circadian trough in order to determine the best pharmacological agent to target fatigue.
Co-Primary- to assess whether ixekizumab Q4W is superior to placebo at Week 12 (Visit 7) in the treatment of pediatric subjects(children and adolescents) with moderate-to-severe plaque psoriasis as measured by PASI 75 and by sPGA (0,1)Gated…
Primary objective: To investigate whether either melatonin or temazepam is superior to placebo in improving subjective sleep quality and to investigate whether melatonin is non-inferior to temazepam in acute hospitalized older patients.Secondary…
Primary objective:-To assess whether ixekizumab is superior to adalimumab at Week 24 in the treatment of patients with active PsA as measured by American Collegeof Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI 100)Major…
Objectives: The primary objectives of the study are to assess whether 80 mg LY2439821 every 2 weeks (Q2W) or every 4 weeks (Q4W) is:* Superior to placebo at Week 12 in the treatment of patients with moderate-to-severe plaque Ps as measured by: o…
Primary objective:-To evaluate in patients having achieved a state of sustained remission whether the ixekizumab treatment group is superior to the placebo group in maintaining response during the randomized-withdrawal periodSecondary objectives:-To…
Primary objective: To assess whether ixekizumab is superior to placebo at Week 12 in the treatment of patients with moderate-to-severe genital psoriasisMajor Secondary Objective:To assess whether ixekizumab is superior to placebo at Week 12 in the…
To evaluate the efficacy of ixekizumab in children with JIA subtypes of ERA (including JoAS) and JPsA based on the JIA American College ofRheumatology (ACR) 30 response